Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Medication Errors Director To Join The Private Sector

This article was originally published in The Pink Sheet Daily

Executive Summary

Jerry Phillips will join the Drug Safety Institute after 30 years in the Public Health Service. He will continue his work assessing the safety of drug names; a pending FDA guidance will likely prompt companies to increase the volume of nomenclature studies they conduct.

You may also be interested in...



FDA Handling Of Antidepressant Inquiry “Troubles” Senate Investigators

Finance Committee staff continues its inquiry into how FDA handled information on a possible link between antidepressants and suicidality. A June 2 letter asks for contact information of former Office of Drug Safety employees and a list of meetings between CDER officials and manufacturers.

FDA Handling Of Antidepressant Inquiry “Troubles” Senate Investigators

Finance Committee staff continues its inquiry into how FDA handled information on a possible link between antidepressants and suicidality. A June 2 letter asks for contact information of former Office of Drug Safety employees and a list of meetings between CDER officials and manufacturers.

FDA Drug Name Review: 31% of Proposed Names “Unacceptable” in 2002

The Division of Medication Errors & Technical Support processed 274 proprietary name consults in fiscal 2002, of which 86 were unacceptable, according to the Office of Drug Safety’s 2002 annual report.

Topics

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel